Business Development Needs Market Access Earlier Than Ever

Business development decisions in pharma and biotech are increasingly being made in a more complex access environment.

Pipeline assets are being evaluated earlier. Deal teams are moving quickly. Commercial forecasts are under pressure. At the same time, payer expectations, pricing scrutiny, evidence requirements, and contracting dynamics are shifting faster than traditional diligence timelines can always accommodate.

That creates a real risk: organizations may move forward on an asset before fully understanding what the market will actually allow.

For business development teams, clinical promise and commercial potential are no longer enough. An asset may look attractive on paper, but its long-term value depends on whether payers, providers, health systems, and other access stakeholders will support the strategy behind it.

Market access needs to be part of that evaluation much earlier.

The Access Assumptions Behind Every Deal

Every acquisition, licensing opportunity, or pipeline investment carries a set of market access assumptions.

Teams may be asking:

Will payers view this asset as meaningfully differentiated?

What evidence will be required to support favorable coverage?

How much pricing flexibility exists in this category?

Will step therapy, prior authorization, or other utilization management barriers limit uptake?

Can the value story support the forecast?

Where could contracting pressure emerge?

These are not late-stage questions. They directly affect valuation, launch planning, evidence generation, and commercial strategy.

When market access input enters the process too late, teams may find themselves trying to solve avoidable problems after major business decisions have already been made.

Traditional Diligence Is Not Always Built for Today’s Market

Traditional market research and advisory board models can still be valuable, but they are not always fast or flexible enough for today’s business development timelines.

eMAX Health materials note that traditional approaches can take several weeks to generate insight and often lack ongoing dialogue. MAVA was built to address this gap by giving teams access to dedicated payer and provider panels, real-time dialogue, rapid polls, direct messaging, and survey tools through a digital engagement platform.

That speed matters. When teams are evaluating an asset, preparing for a transaction, or deciding whether a pricing and access strategy is realistic, waiting months for directional feedback can create unnecessary risk.

Market access insight needs to move at the pace of business development.

Earlier Market Access Input Can Change the Decision

Bringing market access into business development earlier helps teams pressure-test the assumptions that often drive deal value.

For example, access input can help clarify whether an asset’s perceived differentiation is strong enough to support the expected price. It can identify evidence gaps before they become launch barriers. It can expose payer concerns around comparator selection, endpoint relevance, contracting expectations, or budget impact.

It can also help teams determine whether a product’s commercial potential is being overestimated — or, just as importantly, whether an asset has access value that has not yet been fully recognized.

In eMAX Health’s MAVA materials, one business development leader notes: “Our biggest challenge is evaluating assets to acquire. MAVA is a valuable tool that augments our due diligence process by getting true insight from decision makers in the market.”

That is the core issue. Business development teams do not just need more internal modeling. They need market-facing validation from the stakeholders who will ultimately influence access.

Market Access Is Now a BD Advantage

The companies that involve market access earlier are better positioned to make more informed decisions.

They can evaluate assets with a clearer understanding of:

pricing and contracting feasibility

payer-perceived value

evidence requirements

likely access restrictions

forecast risk

launch readiness implications

This does not mean slowing down BD. It means making business development more precise.

Earlier access insight can help teams move faster because they are not relying solely on assumptions, analogs, or internal consensus. They can make decisions with greater confidence and reduce the risk of discovering major access challenges too late.

A More Dynamic Model for Asset Evaluation

Today’s business development environment requires a more dynamic approach to market access insight.

MAVA connects life sciences teams with a network of more than 5,000 stakeholder advisors and provides response dialogue within five business days, with support from eMAX Health subject matter experts and tools for summaries, dashboards, and follow-up questions.

This type of model allows teams to ask timely questions during diligence, revisit assumptions as new information emerges, and test access strategy before decisions become difficult to change.

That is especially important in categories where payer scrutiny is high, pricing pressure is intensifying, or evidence expectations are still evolving.

The Bottom Line

Business development decisions are too important to be separated from market access reality.

As access dynamics become more complex, BD teams need earlier, faster, and more actionable insight into how the market may respond. Market access should not be treated as a downstream planning function. It should be part of the asset evaluation process from the beginning.

Because the value of an asset is not only defined by what it can do clinically.

It is also defined by whether the market will recognize, reimburse, and support that value.